Skip to main content

Leukemia

Outcomes for Patients Receiving Ibrutinib with or without Antifungal Therapy

Kori Daniels, PharmD, BCOP; Arpita Gandhi, PharmD, BCOP; Locke Bryan, MD; Amber Clemmons, PharmD, BCOP

Onureg FDA Approved for Adults with AML in Remission

Retrospective Study of Single Cord Blood Transplantation for Patients with AML Aged ≥60 Years

Enasidenib Monotherapy with Addition of Azacitidine in Nonresponders Effective in Older Patients with Newly Diagnosed, IDH2-Mutated AML

The HARMONY Alliance: Novel Insights into Genomic Classification and Prognosis in Acute Myeloid Leukemia

Characteristics and Prognostic Effects of IDH Mutations Across the Age Spectrum in AML: A Collaborative Analysis

Effect of Early Blood Counts on Response and Overall SurvEffect of Early Blood Counts on Response and Overall Survival Following Glasdegib + LDAC in Newly Diagnosed AMLival Following Glasdegib + LDAC in Newly Diagnosed AML

Venetoclax plus Standard Intensive AML Induction/Consolidation with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML

Clinical Outcomes for Treatment-Naïve Patients with AML Ineligible for Intensive Chemotherapy Receiving Azacitidine or Decitabine

SAL-DaunoDouble Trial Interim Analysis: Single versus Double Induction with 7+3 for Patients with Newly Diagnosed AML

1
2
3
4
5
6
7

Page 4 of 8
Results 31 - 40 of 78